Product Description
Mechanisms of Action: COX Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Austria | Brazil | Bulgaria | Chile | China | Dominican Republic | Egypt | Hong Kong | Hungary | India | Indonesia | Italy | Mexico | Morocco | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Spain | Taiwan | Turkey | Ukraine | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Acute Pain
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2004-001069-17 | P4 |
Completed |
Acute Pain |
2005-03-06 |